N/A
Manufactured by Lupin Pharmaceuticals, Inc.
70,851 FDA adverse event reports analyzed
Last updated: 2026-04-14
DOXYCLYCLINE HYCLATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Lupin Pharmaceuticals, Inc.. The most commonly reported adverse reactions for DOXYCLYCLINE HYCLATE include DRUG HYPERSENSITIVITY, FATIGUE, NAUSEA, PAIN, RASH. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for DOXYCLYCLINE HYCLATE.
Out of 15,907 classified reports for DOXYCLYCLINE HYCLATE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 70,851 FDA FAERS reports that mention DOXYCLYCLINE HYCLATE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG HYPERSENSITIVITY, FATIGUE, NAUSEA, PAIN, RASH, HEADACHE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Lupin Pharmaceuticals, Inc. in connection with DOXYCLYCLINE HYCLATE. Always verify the specific product and NDC with your pharmacist.